{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:45:19Z","timestamp":1794375919984,"version":"4.9.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014475","name":"Pfizer Health Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014475","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018288","name":"AstraZeneca Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018288","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Awareness of transthyretin amyloid cardiomyopathy (ATTR-CM) has increased over the years due to diagnostic and therapeutic developments. Timely initiation of novel disease-modifying treatments improves both morbidity and mortality, which underlines the necessity for a prompt diagnosis. Nevertheless, early diagnosis of ATTR-CM remains challenging. This is a retrospective observational cohort study of patients diagnosed with ATTR-CM. Between 2016 and 2023, 87 patients were diagnosed with cardiac amyloidosis of which 65 (75%) patients with ATTR-CM and 22 (25%) patients with light chain amyloidosis. This study included 65 ATTR-CM patients (mean age 77\u2009\u00b1\u20097\u00a0years; 86% male) of whom 59 (91%) with wild-type ATTR-CM (ATTRwt) and six (9%) with variant ATTR-CM. We observed a surge in ATTR-CM diagnoses from 3 patients\/year (2016\u20132020) to 16 patients\/year (2021\u20132023), driven by ATTRwt. Nevertheless, the interval between the onset of heart failure symptoms and ATTR-CM diagnosis has not changed significantly (2016\u20132020 27.3\u00a0months [18.6\u201362.4]; 2021\u20132023 30.0\u00a0months [8.6\u201357.2]; <jats:italic>p<\/jats:italic>\u2009=\u20090.546), driven by time to referral. Red flags for ATTR-CM preceded diagnosis by several years: left ventricular hypertrophy (79%, 5.8\u00a0years [3.3\u20137.0]) and carpal tunnel syndrome (49%, 6.8\u00a0years [2.3\u201312.1]). Despite the presence of typical red flags, symptom-to-diagnosis duration has remained similar driven by time to referral. Improved recognition of red flags for ATTR-CM could reduce the time to diagnosis and improve overall recognition.<\/jats:p>","DOI":"10.1007\/s00380-024-02408-3","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T18:02:56Z","timestamp":1715018576000},"page":"857-866","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Changes in the diagnostic trajectory of transthyretin cardiac amyloidosis over six years"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0763-7551","authenticated-orcid":false,"given":"Anouk","family":"Achten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa P. M.","family":"van Empel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerremy","family":"Weerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Mourmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Beckers-Wesche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Spanjers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno","family":"Gingele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Brunner-La Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sanders-van Wijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Knackstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"issue":"4","key":"2408_CR1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.2140","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A (2021) Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail 23(4):512\u2013526","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"2408_CR2","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","volume":"6","author":"OF AbouEzzeddine","year":"2021","unstructured":"AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, Noseworthy PA, Johnson GB, Dunlay SM, Borlaug BA, Chareonthaitawee P, Roger VL, Dispenzieri A, Grogan M, Redfield MM (2021) Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol 6(11):1267\u20131274","journal-title":"JAMA Cardiol"},{"issue":"2","key":"2408_CR3","doi-asserted-by":"publisher","first-page":"oeac011","DOI":"10.1093\/ehjopen\/oeac011","volume":"2","author":"M Brons","year":"2022","unstructured":"Brons M, Muller SA, Rutten FH, van der Meer MG, Vrancken AFJE, Minnema MC, Baas AF, Asselbergs FW, Oerlemans MIFJ (2022) Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience. Eur Heart J Open 2(2):oeac011","journal-title":"Eur Heart J Open"},{"issue":"9","key":"2408_CR4","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","volume":"8","author":"VS Hahn","year":"2020","unstructured":"Hahn VS, Yanek LR, Vaishnav J, Ying W, Vaidya D, Lee YZJ, Riley SJ, Subramanya V, Brown EE, Hopkins CD, Ononogbu S, Perzel Mandell K, Halushka MK, Steenbergen C Jr, Rosenberg AZ, Tedford RJ, Judge DP, Shah SJ, Russell SD, Kass DA, Sharma K (2020) Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC Heart Fail 8(9):712\u2013724","journal-title":"JACC Heart Fail"},{"issue":"1","key":"2408_CR5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/ehf2.13110","volume":"8","author":"K Lindmark","year":"2021","unstructured":"Lindmark K, Pilebro B, Sundstr\u00f6m T, Lindqvist P (2021) Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic. ESC Heart Fail 8(1):745\u2013749","journal-title":"ESC Heart Fail"},{"issue":"2","key":"2408_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","volume":"2","author":"SF Mohammed","year":"2014","unstructured":"Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM (2014) Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2(2):113\u2013122","journal-title":"JACC Heart Fail"},{"issue":"3","key":"2408_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L (2008) Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 40(3):232\u2013239","journal-title":"Ann Med"},{"issue":"8","key":"2408_CR8","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.mayocp.2021.04.021","volume":"96","author":"C Fumagalli","year":"2021","unstructured":"Fumagalli C, Zampieri M, Perfetto F, Zocchi C, Maurizi N, Tassetti L, Ungar A, Gabriele M, Nardi G, Del Monaco G, Baldini K, Tomberli A, Tomberli B, Marchionni N, Di Mario C, Olivotto I, Cappelli F (2021) Early diagnosis and outcome in patients with wild-type transthyretin cardiac amyloidosis. Mayo Clin Proc 96(8):2185\u20132191","journal-title":"Mayo Clin Proc"},{"issue":"17","key":"2408_CR9","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, Gonz\u00e1lez-Duarte A, Sarswat N, Sekijima Y, Tahara N, Taylor MS, Kubanek M, Donal E, Palecek T, Tsujita K, Tang WHW, Yu W-C, Obici L, Sim\u00f5es M, Fernandes F, Poulsen SH, Diemberger I, Perfetto F, Solomon SD, Di Carli M, Badri P, White MT, Chen J, Yureneva E, Sweetser MT, Jay PY, Garg PP, Vest J, Gillmore JD (2023) Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med 389(17):1553\u20131565","journal-title":"N Engl J Med"},{"issue":"11","key":"2408_CR10","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007\u20131016","journal-title":"N Engl J Med"},{"issue":"10","key":"2408_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.acvd.2023.07.003","volume":"116","author":"T Damy","year":"2023","unstructured":"Damy T, Zaroui A, de Tournemire M, Kharoubi M, Gounot R, Galat A, Guendouz S, Funalot B, Itti E, Roulin L, Audard V, Fanen P, Leroy V, Poulot E, Belhadj K, Mallet S, Deep Singh Chadah G, Plant\u00e9-Bordeneuve V, Gendre T, Chevalier X, Guignard S, Bequignon E, Bartier S, Folliguet T, Lemonier F, Audureau E, Tixier D, Canoui-Poitrine F, Lefaucheur JP, Souvannanorath S, Authier FJ, Maupou S, Hittinger L, Molinier-Frenkel V, David JP, Broussier A, Oghina S, Teiger E (2023) Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France. Arch Cardiovasc Dis 116(10):433\u2013446","journal-title":"Arch Cardiovasc Dis"},{"issue":"5","key":"2408_CR12","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1002\/ehf2.12793","volume":"7","author":"D Dang","year":"2020","unstructured":"Dang D, Fournier P, Cariou E, Huart A, Ribes D, Cintas P, Roussel M, Colombat M, Lavie-Badie Y, Carri\u00e9 D, Galinier M, Lairez O (2020) Gateway and journey of patients with cardiac amyloidosis. ESC Heart Fail 7(5):2418\u20132430","journal-title":"ESC Heart Fail"},{"issue":"2","key":"2408_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.recesp.2019.12.017","volume":"74","author":"\u00c1 L\u00f3pez-Sainz","year":"2021","unstructured":"L\u00f3pez-Sainz \u00c1, Hernandez-Hernandez A, Gonzalez-Lopez E, Dom\u00ednguez F, Restrepo-Cordoba MA, Cobo-Marcos M, G\u00f3mez-Bueno M, Hernandez-Perez FJ, Oteo JF, Mirelis JG, Cavero MA, Mo\u00f1ivas V, Mingo Santos S, de Haro-Del Moral FJ, Krsnik I, Salas C, Bornstein B, Brice\u00f1o A, L\u00f3pez JA, V\u00e1zquez J, Alonso-Pulp\u00f3n L, Segovia J, Garcia-Pavia P (2021) Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center. Rev Esp Cardiol (Engl Ed) 74(2):149\u2013158","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"3","key":"2408_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10741-021-10080-2","volume":"27","author":"JN Nativi-Nicolau","year":"2022","unstructured":"Nativi-Nicolau JN, Karam C, Khella S, Maurer MS (2022) Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev 27(3):785\u2013793","journal-title":"Heart Fail Rev"},{"issue":"11","key":"2408_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s12471-019-1299-1","volume":"27","author":"M Oerlemans","year":"2019","unstructured":"Oerlemans M, Rutten KHG, Minnema MC, Raymakers RAP, Asselbergs FW, de Jonge N (2019) Cardiac amyloidosis: the need for early diagnosis. Neth Heart J 27(11):525\u2013536","journal-title":"Neth Heart J"},{"issue":"9","key":"2408_CR16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/00015385.2021.1976450","volume":"77","author":"P Debonnaire","year":"2022","unstructured":"Debonnaire P, Claeys M, De Smet M, Trenson S, Lycke M, Demeester C, Van Droogenbroeck J, De Vriese AS, Verhoeven K, Vantomme N, Van Meirhaeghe J, Willandt B, Lambert M, de Paepe P, Delanote J, De Geeter F, Tavernier R (2022) Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications. Acta Cardiol 77(9):791\u2013804","journal-title":"Acta Cardiol"},{"issue":"4","key":"2408_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jaccao.2021.08.009","volume":"3","author":"J Nativi-Nicolau","year":"2021","unstructured":"Nativi-Nicolau J, Siu A, Dispenzieri A, Maurer MS, Rapezzi C, Kristen AV, Garcia-Pavia P, LoRusso S, Waddington-Cruz M, Lairez O, Witteles R, Chapman D, Amass L, Grogan M (2021) Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the transthyretin amyloidosis outcomes survey. JACC CardioOncol 3(4):537\u2013546","journal-title":"JACC CardioOncol"},{"issue":"1","key":"2408_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","volume":"10","author":"MH Rozenbaum","year":"2021","unstructured":"Rozenbaum MH, Large S, Bhambri R, Stewart M, Whelan J, van Doornewaard A, Dasgupta N, Masri A, Nativi-Nicolau J (2021) Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. Cardiol Ther 10(1):141\u2013159","journal-title":"Cardiol Ther"},{"issue":"11","key":"2408_CR19","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, Dember LM, Frantz JG, Hershberger RE, Maurer MS, Nativi-Nicolau J, Sanchorawala V, Sheikh FH (2023) 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis. J Am Coll Cardiol 81(11):1076\u20131126","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2408_CR20","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","volume":"1","author":"A Castano","year":"2016","unstructured":"Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, Pozniakoff T, Ruberg FL, Miller EJ, Berk JL, Dispenzieri A, Grogan M, Johnson G, Bokhari S, Maurer MS (2016) Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 1(8):880\u2013889","journal-title":"JAMA Cardiol"},{"issue":"2","key":"2408_CR21","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/ehf2.13833","volume":"9","author":"M Henkens","year":"2022","unstructured":"Henkens M, Weerts J, Verdonschot JAJ, Raafs AG, Stroeks S, Sikking MA, Amin H, Mourmans SGJ, Geraeds CBG, Sanders-van Wijk S, Barandiar\u00e1n Aizpurua A, Uszko-Lencer N, Krapels IPC, Wolffs PFG, Brunner HG, van Leeuwen REW, Verhesen W, Schalla SM, van Stipdonk AWM, Knackstedt C, Li X, Abdul Hamid MA, van Paassen P, Hazebroek MR, Vernooy K, Brunner-La Rocca HP, van Empel VPM, Heymans SRB (2022) Improving diagnosis and risk stratification across the ejection fraction spectrum: the Maastricht Cardiomyopathy registry. ESC Heart Fail 9(2):1463\u20131470","journal-title":"ESC Heart Fail"},{"issue":"1","key":"2408_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28(1):1-39.e14","journal-title":"J Am Soc Echocardiogr"},{"issue":"30","key":"2408_CR23","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39(30):2799\u20132806","journal-title":"Eur Heart J"},{"issue":"14","key":"2408_CR24","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","volume":"135","author":"MS Maurer","year":"2017","unstructured":"Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C (2017) Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 135(14):1357\u20131377","journal-title":"Circulation"},{"issue":"6","key":"2408_CR25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/ejhf.2823","volume":"25","author":"G Tini","year":"2023","unstructured":"Tini G, Milani P, Zampieri M, Caponetti AG, Fabris F, Foli A, Argir\u00f2 A, Mazzoni C, Gagliardi C, Longhi S, Saturi G, Vergaro G, Aimo A, Russo D, Varr\u00e0 GG, Serenelli M, Fabbri G, De Michieli L, Palmiero G, Ciliberti G, Carigi S, Sessarego E, Mandoli GE, Ricci Lucchi G, Rella V, Monti E, Gardini E, Bartolotti M, Crotti L, Merli E, Mussinelli R, Vianello PF, Cameli M, Marzo F, Guerra F, Limongelli G, Cipriani A, Perlini S, Obici L, Perfetto F, Autore C, Porto I, Rapezzi C, Sinagra G, Merlo M, Musumeci B, Emdin M, Biagini E, Cappelli F, Palladini G, Canepa M (2023) Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study. Eur J Heart Fail 25(6):845\u2013853","journal-title":"Eur J Heart Fail"},{"key":"2408_CR26","unstructured":"World Health Organization DoDaADoD (2020) WHO methods and data sources for country-level causes of death 2000\u20132019. Global Health Estimates Technical Paper WHO\/DDI\/DNA\/GHE\/20202"},{"issue":"24","key":"2408_CR27","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","volume":"38","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2017","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gagliardi C, Dominguez F, Quarta CC, de Haro-Del Moral FJ, Milandri A, Salas C, Cinelli M, Cobo-Marcos M, Lorenzini M, Lara-Pezzi E, Foffi S, Alonso-Pulpon L, Rapezzi C, Garcia-Pavia P (2017) Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J 38(24):1895\u20131904","journal-title":"Eur Heart J"},{"issue":"12","key":"2408_CR28","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jcmg.2023.05.002","volume":"16","author":"X Arana-Achaga","year":"2023","unstructured":"Arana-Achaga X, Goena-Vives C, Villanueva-Benito I, Solla-Ruiz I, Rengel Jimenez A, Gaspar TI, Urreta-Barallobre I, Barge-Caballero G, Seijas-Marcos S, Cabrera E, Garcia-Pav\u00eda P, Basurte Elorz MT, Ayestar\u00e1n NM, Sierra LT, Robledo I\u00f1arritu M, Lozano-Bahamonde A, Escolar-Perez V, G\u00f3mez-Ram\u00edrez C, Alzola E, Andr\u00e9s RN, Francisco Matias JL, Limeres Freire J, Armengou Arxe A, Negre Bus\u00f3 M, Piqueras-Flores J, Mart\u00ednez-Del R\u00edo J, Onaindia Gandarias JJ, Rodriguez Sanchez I, Querejeta Iraola R (2023) Development and validation of a prediction model and score for transthyretin cardiac amyloidosis diagnosis: T-Amylo. JACC Cardiovasc Imaging 16(12):1567\u20131580","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11","key":"2408_CR29","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.jcmg.2021.03.032","volume":"14","author":"G Captur","year":"2021","unstructured":"Captur G, Manisty CH, Raman B, Marchi A, Wong TC, Ariga R, Bhuva A, Ormondroyd E, Lobascio I, Camaioni C, Loizos S, Bonsu-Ofori J, Turer A, Zaha VG, Augutsto JB, Davies RH, Taylor AJ, Nasis A, Al-Mallah MH, Valentin S, Arenaza DPd, Patel V, Westwood M, Petersen SE, Li C, Tang L, Nakamori S, Nezafat R, Kwong RY, Ho CY, Fraser AG, Watkins H, Elliott PM, Neubauer S, Lloyd G, Olivotto I, Nihoyannopoulos P, Moon JC (2021) Maximal wall thickness measurement in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 14(11):2123\u20132134","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"2408_CR30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/joim.13200","volume":"289","author":"F Cappelli","year":"2021","unstructured":"Cappelli F, Zampieri M, Fumagalli C, Nardi G, Del Monaco G, Matucci Cerinic M, Allinovi M, Taborchi G, Martone R, Gabriele M, Ungar A, Moggi Pignone A, Marchionni N, Di Mario C, Olivotto I, Perfetto F (2021) Tenosynovial complications identify TTR cardiac amyloidosis among patients with hypertrophic cardiomyopathy phenotype. J Intern Med 289(6):831\u2013839","journal-title":"J Intern Med"},{"key":"2408_CR31","first-page":"517","volume":"47","author":"NP Gannon","year":"2023","unstructured":"Gannon NP, Ward CM (2023) Results of Implementation of Amyloidosis Screening for Patients Undergoing Carpal Tunnel Release. J Hand Surg Am 47:517\u2013525","journal-title":"J Hand Surg Am"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-024-02408-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-024-02408-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-024-02408-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T09:04:29Z","timestamp":1726477469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-024-02408-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2408"],"URL":"https:\/\/doi.org\/10.1007\/s00380-024-02408-3","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"26 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Pfizer and Astra Zeneca have provided an unrestricted research grant to the Maastricht University Medical Centre. The provider of the research grant had no influence on the study design, data collection, analyses, interpretation of the data, and writing of the report. AA and CK have received speakers\u2019 honoraria from Pfizer paid the Maastricht University Medical Centre. CK has received consulting fees from Pfizer, Novartis, BMS and Alnylam paid to the Maastricht University Medical Centre.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}